Biogen

Biogen is bolstering the company’s multiple sclerosis pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic MR-004, which is being assessed for the potential treatment of gait deficits in MS.

Published April 07, 2022 By Alex Keown BioSpace Jazz Pharmaceuticals continues to advance its efforts toward becoming a leading oncology company via a key licensing deal with Werewolf Therapeutics for […]

Biohaven, a clinical-stage biopharmaceutical company that innovates late-stage products for neurological and neuropsychiatric diseases, announced two major growth achievements.

Biohaven Pharmaceutical Holding Company Ltd. entered into a worldwide license agreement with Bristol Myers Squibb Co. for the development and commercialization rights to the novel, Phase 3-ready anti-myostatin adnectin taldefgrobep alfa for spinal muscular atrophy (SMA)

BioNTech and Medigene announced a global agreement to develop T-cell immunotherapies against cancer. The three-year collaboration will focus on multiple solid tumor targets. 

Roivant Sciences launched the new subsidiary Hemavant, which hit the ground running with a licensing agreement from Eisai for RVT-2001, a potential first-in-class small molecule SF3B1 modulator.

Takeda

With two assets licensed from Takeda, Oak Hill Bio launched with a focus on developing therapeutics for patients and extremely preterm infants who are suffering from rare autoimmune diseases.

Pfizer building

Pfizer and Ionis Pharmaceuticals announced that the former is abandoning the vupanorsen program for cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG), or high triglycerides. Pfizer was leading the program.

Kyverna Therapeutics secured an additional $85 million following a successful Series B financing round to support various projects in the company’s pipeline of therapies for autoimmune and inflammatory diseases. 

Prellis Biologics entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing the Bay Area biotechnology company’s first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO).